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assembled 78 treatment plans, that they were generated, 36 
IMAT, 18 3DCRT, 3 IMRT, 9 helical irradiation and 12 robotic 
radiosurgery. All gathered data were finally imported into 
one treatment planning system for evaluating different 
planning strategies. 
 
Results: In all plans, the dosimetric coverage of the target 
volume and the dose to OARs were within clinical limits. The 
coverage of the PTV were disclosed: CICRU =1.0(0.9-1.1); 
CI65 =0.7(0.4-1.0); HI=0.3(-0.3-0.5); Dmin/Dmax=0.6(0.5-
0.7); D2%,=64.6(47.5-71.3)Gy; D98%=47.2(39.5-68.6)Gy; 
Dmiddle=57.8(47.3-65.8)Gy. 
In the 3DCRT Plans, the mean dose in the PTV was on 
average, 3 Gy higher than dynamic techniques; MU and 
irradiation time were by the factor of 2-3 higher in the 
dynamic techniques. Dose to the OARs for the 1st and 2nd 
patient is as bellows: Dmedi, ipsilat. lung = 4.9 (3.2-8.8)Gy; 
Dmax, esophagus =7.7(0.4-16.1)Gy. V35Gy, rips =10(0.6-
43.7). For the 3rd one: Dmedi., ipsilat. lung = 8.3(6.8-10)Gy; 
Dmedi.,contralat. lung = 2.3(1.4-4.7)Gy Dmax, 
esophagus=20.7(11.3-27.7)Gy. 




Conclusion: All irradiation techniques were applicable for 
clinical use, the resulting dose distribution were quite 
similar. By comparison, the statistically significant 
differences between the users were greater than the 
differences between the techniques. This demonstrate that 
strict constrains and works like the DEGRO reference paper 
(Guckenberger et al) are necessary to homogenize the SBRT 
planning at a national level. 
This study reports the results of the irradiation planning for 
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Purpose or Objective: Management of pelvic sidewall 
recurrence in gynaecological cancers is a challenging clinical 
scenario. Sciatic nerve involvement may exclude surgery and 
cause intractable symptoms that are difficult to palliate. In 
the context of re-irradiation, high doses of radiation without 
consideration of the sciatic nerve can cause irreversible 
nerve damage, yet this has not traditionally been included as 
an OAR.  
The aims of this study were to develop dose target 
constraints for re-irradiation of the sciatic nerve, and to 
assess the impact of nerve-sparing optimisation on target 
volume coverage and OAR sparing with stereotactic 
radiotherapy techniques. 
 
Material and Methods: Cumulative dose constraints for re-
irradiation were derived assuming prior pelvic radiotherapy 
of 50Gy (EQD2) and allowing nerve recovery values of 50% 
and 100%. Treatment plans were produced for 10 patients 
with recurrent gynaecological cancer delivering 30 Gy in 5 
fractions. Two normalisation methods were assessed: ICRU 83 
type normalisation and prescription (ICRU); and stereotactic 
radiosurgery convention of prescribing to the isodose 
covering 95% PTV allowing maximum doses of ~125% (SRS). 
For each method, plans were optimised with and without 
sciatic nerve sparing targets. Sciatic nerve roots were 
contoured from sacral foramina until the nerve exits the 
pelvis. Nerve sparing plans were optimised to minimize dose 
to nerve PRV while maintaining PTV coverage. Doses to GTV, 
PTV, OAR and sciatic nerve were compared. 
 
Results: All 40 plans met the PTV targets with >95% PTV 
coverage by the specified isodose. The sciatic nerve was 
involved in 3 patients, close proximity (<5 mm) in 4 patients 
and more than 5 mm distant from PTV in 3 patients. The dose 
targets were Dmax 32 Gy when there was nerve involvement 
and 21.9 Gy when the nerve was distant from tumour. For all 
patients, the sciatic nerve dose was reduced with each 
technique: median Dmax with ICRU from 28.8 Gy to 22.3 GY 
and with SRS from 28.7 Gy to 19.9 Gy. For patients with overt 
nerve involvement, median Dmax was reduced from 34.9 Gy 
to 32.1 Gy with SRS. Nerve sparing was achieved without 
significantly decreasing GTV mean doses or increasing bowel 
doses.  
 
Conclusion: The sciatic nerve should be an OAR for re-
irradiation of sidewall recurrence. Optimisation using a 
sciatic nerve PRV can significantly reduce dose to nerve by up 
40% (EQD2-2) while having minimal effect on GTV coverage or 
bowel doses. Feasible dose targets depend on proximity of 
nerve to GTV and clinical scenario.  
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Purpose or Objective: Over the last half century we have 
seen remarkable improvements in the survival of pediatric 
cancer patients. Therefore, the impact of cancer and its 
treatment must be assessed. Furthermore, the radiotherapy 
technique must be well selected in order to minimize the 
secondary effects. Since hearing loss is a common late effect 
of radiotherapy, the purpose of this study was to compare 
three different treatment techniques and to evaluate the 
dose to the cochleas and supretentorial brain, in children 
treated with radiotherapy for medulloblastoma.  
 
Material and Methods: A total of 121 children were treated 
in our department with radiotherapy for CNS tumors, 
between January 2000 and December 2014. Those who were 
diagnosed with medulloblastoma were included. A total of 29 
children fulfilled these criteria. The adopted treatment plan 
consisted of a first phase with three-dimensional conformal 
radiotherapy (3D-CRT) to the craniospinal region (prescribed 
doses from 23.4 to 36.0 Gy) followed with a boost to the PTV 
(posterior fossa/tumor bed) with prescribed doses of 18.0 or 
31.6 Gy depending on the clinical risk-group, high or standard 
risk respectively . For each child, three different treatment 
plans were prepared for the boost phase: one with 
conventional 2 parallel opposed fields (CRT), one more 
complex with 3D conformal radiotherapy (3D-CRT) and 
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another with IMRT. The original plans delivered to the 
patients were not considered in this study because treatment 
techniques have been changing since 2000 and were not 
uniform within the selected group. All plans assured PTV 
coverage according to ICRU 83 criteria. Cochleas and 
supratentorial brain mean doses, as organs , were analyzed 
using QUANTEC values and compared for each plan. 
 
Results: Among 29 children, 22 were males. The median age 
at diagnosis was 8.66 years. At the beginning of treatment, 
their age range from 3.26 to 15.47 years old. The average 
mean dosesto the OAR analyzed are presented in Table 1. 




Conclusion: The plans for the CRT technique, with 2 parallel 
opposed fields, produced worst results for both OARs. The 
IMRT technique was slightly superior to the 3D-CRT in terms 
of mean dose of cochleas but conducted, in average, to 
higher dose values to the supratentorial brain. Based on 
these results we decided to adopt the 3D-CRT technique for 
the boost phase in high-risk group and IMRT for the standard-
risk group, considering the higher potencial impact in the 
cochleas mean doses in this risk-group.  
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Purpose or Objective: This work is to present the treatment 
planning workflow and delivery technique for the first 
application of linac based spatially fractionated mini-beam 
radiotherapy within a clinical trial of canine brain tumor 
treatments. The motivation for this investigation originates 
from work performed using synchrotron generated micro-
beams (MRT) which have shown promising results in 
preserving brain architecture while killing tumor cells. 
Spatial fractionation of radiation using arrays of parallel 
micro-planar beams is a developing technique with many 
unknowns and limitations. To further research this technique 
and to potentially enable MRT for human treatments, a mini-
beam collimator has been designed for use with a linac and a 
Monte Carlo (MC) beam model has been commissioned for 
clinical treatment planning. 
 
Material and Methods: Patient population was selected from 
client-owned canines with spontaneously occurring brain 
tumors. Patients were placed under general anesthesia and 
positioned prone within stereotactic immobilization 
equipment during imaging and treatment delivery. CT and 
MRI images were used for contouring. The planning technique 
utilized an arrangements of static mini-beams. Beam angles 
were chosen such that the treatment depth was within 20% 
for each beam to minimize beam broadening with depth and 
blurring of the peak and valley doses. Beam apertures were 
defined with the MLC leaves set 3 mm back from the PTV. 
The mini-beam collimated dose distributions were calculated 
to a statistical uncertainty of ±1.0 % within a voxel size of 0.5 
mm. Beam weighting was equalized and the plan normalized 
such that the prescription dose was delivered to an ICRU dose 
reference point within the PTV. Deliver quality assurance 
(DQA) was performed by measuring the absolute dose from 
each beam using an ion chamber within a solid water 
phantom. 
 
Results: Contouring and beam arrangement, which included 
MLC placement, was performed within the clinical treatment 
planning system (TPS). The DICOM plan was then exported to 
the MC treatment planning system for mini-beam dose 
calculation. The distribution was reviewed and DVHs assessed 
for normal tissue tolerances. The final step was to transcribe 
the calculated MUs back to the original TPS. Planning 
turnaround time was 2 days. The MC calculations were 
initiated overnight at the end of day 1. Day 2 was spent 
reviewing the plan, generating the DQA plan, and finalizing 
the treatment parameters into the record-and-verify system 
(RVS). DQA output measurements of the treatment fields 
agreed with the calculated dose to within 1.5%. An image of 
the patient dose distribution and setup is shown in figure 1. 
 
 
Conclusion: A workflow for mini-beam treatments that 
includes the planning technique, MC dose calculation 
method, DQA process, and data integration into a RVS has 
been established. This clinical dataset represents the first 
treatment planning study of linac based mini-beam patients. 
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Purpose or Objective: The aim of this study is to investigates 
different strategies in choosing, in a mathematical way, the 
structure set that best fit a Dose Painting (DP) distribution, 
based on ADC maps, to be submitted to the optimization 
process within the TomoTherapy TPS. 
 
Material and Methods: Hypofractionated Stereotactic 
Radiation Therapy plans in 5 fractions of intracranial GBM for 
six patients were retrospectively realized. 
